The course of cystoid macular oedema (CMO) following extracapsular cataract extraction with posterior chamber intraocular lens implantation was prospectively studied in 44 eyes of 44 consecutive diabetic patients without preoperative CMO. In 50% of eyes CMO was observed 6 weeks after surgery and in 25% was still present at 1 year. The preoperative presence of diabetic retinopathy significantly affected the postoperative onset and persistence ofCMO. CMO occurred postoperatively in only 32% of eyes without pre-existing diabetic retinopathy and in 81% of eyes with pre-existing diabetic retinopathy (p<005). CMO persisted at 1 year after surgery in only 7% of eyes without pre-existing diabetic retinopathy and in 56% of eyes in which diabetic retinopathy persisted (p<001). Angiographic CMO (that is, detectable only on fluorescein angiography) was more common than clinical CMO (detectable on ophthalmoscopic examination as well) in eyes with no pre-existing diabetic retinopathy, whereas clinical CMO was seen more often than angiographic CMO when diabetic retinopathy was present preoperatively (p<001). The course and final visual outcome of angiographic CMO were more favourable than in clinical CMO. Final visual acuity of at least 6/12 was achieved in 86% of eyes with angiographic CMO and in only 33% of eyes with clinical CMO. On the basis of the above findings we believe that cataract extraction should not be recommended for eyes with pre-existing diabetic retinopathy until the vision has deteriorated to at least 6/30-6/60.
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The visual prognosis following cataract surgery in diabetic patients depends on the presence and/ or the severity of existing diabetic retinopathy and its possible aggravation after surgery.'" In particular the visual outcome may be influenced by the postoperative onset of cystoid macular oedema (CMO) which may occur even without onset or aggravation of diabetic retinopathy.
In a previous study we observed a high incidence of progression of diabetic retinopathy' following cataract surgery.7 'Progression' was defined as appearance or worsening ofthe diabetic retinopathy regardless of whether or not CMO was present. However though that study did not deal specifically with the course of maculopathy our clinical impression was that the presence of CMO after cataract extraction is more common in diabetic than in non-diabetic eyes.
The purpose of this prospective study was to investigate the onset and course of CMO following cataract surgery with lens implantation in diabetic patients. The Table 3 . Table 4 summarises the incidence ofCMO and its persistence 1 year after surgery in relation to both the preoperative and the postoperative status of diabetic retinopathy.
Of the 13 eyes with preoperative diabetic retinopathy and postoperative onset of CMO, nine also showed progression of diabetic retinopathy following surgery. Five of these 13 eyes received laser treatment for their postoperative retinopathic changes and eight did not. In the nine eyes that had no diabetic retinopathy preoperatively and developed CMO postoperatively laser treatment was not indicated (Table 4) . Table 5 compares the final visual acuity results in diabetic patients with and without postoperative onset of CMO. In both cases more patients Since preexisting diabetic retinopathy is also a risk factor for its postoperative aggravation,7 which may be associated with CMO, it is possible that the preexistence of diabetic retinopathy may have contributed to the postoperative development of CMO. In this study most of the eyes with postoperative progression of diabetic retinopathy also developed CMO (78%, 14/18), whether diabetic retinopathy had pre-existed (82%, 9/11) or not (71%, 5/7) ( Table 3 ).
In the general population CMO, ifit appears at all after surgery, usually occurs within 6 weeks of the operation, is transitory, and disappears within 6 months." The reported incidence of CMO persisting for 6 months after surgery ranges between 0-9 and 4%." In our control group it persisted in 4%. In the diabetic group however CMO lasted longer and was still evident even after 6 months. We therefore considered CMO as 'persistent' ifit was still present at 1 year after surgery (Table 4) . Persistence of CMO was noted in 25% of the diabetic eyes and like the postoperative incidence of CMO in these eyes varied with the preoperative retinal status (see Table 4 ). If we assume that persistence of CMO for at least 1 year after surgery in diabetic patients is equivalent to its persistence for at least 6 months in the general population then our diabetic patients with no pre-existing diabetic retinopathy did not differ significantly from our control group in this regard (7% v 4% respectively). Eyes with pre-existing diabetic retinopathy that progressed after surgery (89%, 8/9) carried the highest risk of persistence.
Visual acuity of at least 6/12 was achieved by a high percentage of eyes that developed angiographic CMO after surgery, similar to the percentage in the subgroup of operated patients with no pre-existing diabetic retinopathy and no CMO ( The results of this study indicate that after cataract surgery with lens implantation CMO occurs more often and persists for longer in eyes of diabetic than of non-diabetic patients. In addition it is affected by the preoperative retinal status. Eyes with no pre-existing diabetic retinopathy tend to develop angiographic rather than clinical CMO; this seldom persists for longer than 1 year and the final visual outcome resembles that of the general population. In contrast operated eyes with pre-existing diabetic retinopathy tend to develop clinical CMO, which quite often persists for at least 1 year, and the final visual acuity can be expected to be in the range of 6/15-6/30. These findings may act as guidelines when cataract surgery is contemplated for diabetic patients. We would counsel a cautious approach for eyes with pre-existing diabetic retinopathy; surgery should probably not be recommended in such cases until vision has deteriorated to at least 6/30-6/60.
